User:Sunnyuberoi/sandbox

HemopureBold text

Heading text
Hemopure is an oxygen-carrying solution which when administered intravenously can increase the amount of oxygen transported throughout the body. In April 2019, the American Journal of Transplantation published preclinical data demonstrating that Hemopure could replace packed red blood cells (PRBCs) in normothermic kidney perfusion (NMP) – a novel platform which is gaining significant interest in the field of organ transplantation. This technology assesses the organ’s viability before transplantation and requires a perfusion solution to provide adequate oxygen supply to the organ.

The results involved 14 human kidneys obtained from the New England Donor Services (NEDS) after being declined for transplantation by all centers. These kidneys were perfused with either Hemopure (n=7) or packed red blood cells (n=7) to increase oxygen carrying capacity. The study evaluated renal artery resistance, oxygen extraction,  activity, energy stores, production of urine and histological features.

The findings showed that Hemopure performed comparably to packed red blood cells while overcoming logistical and clinical issues associated with red blood cell-based solutions including longer shelf half-lives, ease of use and accessibility, and negligible infectious risks.